Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...

An overview of the top 10 stories from Optometry Times in 2025.

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...

Regeneron has had its hands full this year contending with regulatory setbacks, Amgen's marketed Eylea biosimilar and Roche's hard-charging ophthalmology rival Vabysmo. Next year, the biosimilar ...

This article updates on two key legal cases in healthcare enforcement. First, in Regeneron, after the First Circuit ruled ...

The proposed aflibercept biosimilar is intended to treat ophthalmic disorders. This FDA submission follows the licensing agreement under which Fresenius Kabi will exclusively commercialize the ...

(RTTNews) - Alvotech (ALVO) and Teva Pharmaceutical Industries Ltd. (TEVA) have secured a U.S. license entry date for AVT06, the proposed biosimilar to Regeneron's Eylea, setting the stage for a ...